ECT2 and neoplasm: In our AA prostate contralateral benign-tumor-matched cohort (n = 73), ANLN was shown to be nominally overexpressed in tumors compared to non-malignant (p = 0.06), while ECT2 was significantly overexpressed in tumor compared to non-malignant matched tissue (p < 0.00001) (Figure 4G,H, Table S7).